Description

The purpose of this Notice of Amendment is to notify about the additions of amifampridine, cedazuridine (when used in combination with another drug), etomidate, fedratinib, lefamulin, obiltoxaximab, polatuzumab vedotin, ripretinib, satralizumab and sonidegib to the Prescription Drug List (PDL) for human and/or veterinary use.

Resources

Name	Format	Description	Link
Notice: Prescription Drug List (PDL): Multiple Additions (2020-09-08)	HTML		https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/multiple-additions-2020-09-08.html
Notice: Prescription Drug List (PDL): Multiple Additions (2020-09-08)	HTML		https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/liste-drogues-ordonnance/avis-concernant-modifications/additions-multiples-2020-09-08.html

Tags

Topics

Categories